Desmosomes provide the main intercellular adhesive properties between epidermal keratinocytes. Their distribution becomes uneven in severe dermatitis, multiple allergies and metabolic wasting syndrome due to desmoglein 1 deficiency and the loss of intercellular adhesion or acantholysis. When keratinocytes differentiate from granular cells into cornified cells, desmosomes are transformed into corneodesmosomes and can provide stronger intercellular adhesion. Degradation of corneodesmosomes is a tightly regulated process involving a number of proteases and their inhibitors. Peripheral corneodesmosomes are protected from proteolytic degradation by the tight junction-related structures around them, and this construction provides the basis for the normal basket weavelike structure of the stratum corneum. In Netherton syndrome, which is caused by an absence of the protease inhibitor lymphoepithelial Kazal-type-related inhibitor, premature degradation of corneodesmosomes occurs due to the overactivation of proteases involved in corneodesmosome degradation. Inflammatory peeling skin disease is caused by the absence of corneodesmosin, a unique component of corneodesmosomes. In this disease, corneodesmosomes are structurally abnormal, and their adhesiveness is compromised, which leads to intercellular splitting between the stratum corneum and stratum granulosum. The better we understand desmosome and corneodesmosome ultrastructure in normal and diseased skin, the clearer the physiological and pathological mechanisms of epidermal integrity become.
INTRODUCTION
To better understand the relationship between structural changes and molecular pathology, it is important to describe the structural changes accurately and correlate them with molecular abnormalities. By doing so, we can predict structural pathologies when we encounter a new disease, or we can think of candidate molecules for an unusual structural change. In this review, we will first explain the structural-molecular interactions in desmosomes and corneodesmosomes (CD; modified desmosomes found in cornified cells) and then discuss genetic diseases associated with desmosomes and CD. 1 (For desmosome structural changes in pemphigus, an autoimmune bullous disease against desmosomal proteins, see other publications).
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STRUCTURE AND COMPONENTS OF DESMOSOMES AND CORNEODESMOSOMES
Desmosomes are intercellular adhesion structures that tether adjacent cells and maintain tissue integrity. 1 Desmosomes are also involved in cell signaling, differentiation, inflammation and carcinogenesis. These structures anchor the plasma membranes of two adjacent cells to their intermediate filament cytoskeleton, including keratin filaments ( Fig. 1 ). Desmosomes are well developed in tissues that experience considerable mechanical stress, such as the epidermis and myocardium. The ultrastructure of desmosomes is highly characteristic and several substructures can be identified, including intracellular attachment plaques (the plasma membrane-proximal outer plaque and the intermediate filamentconnected inner plaque), plasma membrane, and desmoglea (extracellular part). An electron-dense midline can be identified in the middle of the desmoglea in a stable desmosome. The absence of this midline structure has been associated with wound healing, keratinocyte motility and mitosis, and observed in diseases such as tylosis with esophageal cancer. 4 The main components of desmosomes are the cadherin, armadillo protein and plakin protein families. Cadherins engage in extracellular adhesive interactions. 3 Desmogleins and desmocollins are members of the cadherin superfamily and transmembrane proteins that form heterophilic and hemophilic dimers in the extracellular space between adjacent cells. In the outer plaque, the armadillo family protein plakoglobin links the cytoplasmic tail of cadherins to desmoplakin, a member of the plakin family. Plakophilin, also an armadillo protein, facilitates lateral interactions between desmosomal cadherin complexes and further strengthens the plaque. In the inner plaque, desmoplakin binds to intermediate filaments. This architectural arrangement tethers desmosomal cadherin adhesive interactions to the intermediate filament cytoskeleton, thereby establishing an integrated adhesive and cytoskeletal network that extends throughout a tissue.
When epidermal keratinocytes are differentiated and move from a granular layer to a cornified layer, the extracellular part of the desmosome loses its electron-dense midline and becomes an electron-dense homogeneous plaque (Fig. 1) . In this process, the plasma membrane is changed into a lipid envelope, the outer plaque is incorporated into the cornified cell envelope, and the inner plaque is embedded in densely packed keratin filaments. These modified desmosomes found in cornified cells are called CD.
Corneodesmosomes are distributed all around the surface of corneocytes in the lower stratum corneum (stratum corneum compactum) but are found only at the peripheral edges of flattened cornified cells in more superficial layers (Fig. 2) , 5 except for the palmoplantar epidermis. These two types of layers correspond to the compact layers and basket weave-like layers observed in conventional formalin-fixed paraffin-embedded skin specimens. It was unclear why CD at the edges of corneocytes remain intact up to the surface of the stratum corneum. Haftek et al. 6 found tight contact areas near CD at the cellular edges and considered them to be derived from tight junctions (TJ). We confirmed the presence of this structure and found that the structure sandwiches CD, and proteases involved in CD degradation cannot access the area sealed by the TJ-related structure. 5 We hypothesized that this TJ-related structure is the base of the site-specific degradation mechanism for CD. 5 Kitajima reported that a freeze-fracture method revealed desmosomes at the stratum granulosum and CD are surrounded by TJ or TJ-like structures, which supports our hypothesis. 7 It has been reported that claudin-1-deficient mice showed abnormal stratum corneum barrier functions. 8 TJ-related structures in the stratum corneum derived from claudin-1-deficient TJ may cause abnormal CD degradation processes followed by barrier dysfunction. A unique and important component of CD is corneodesmosin, a 52-56-kDa glycoprotein synthesized in differentiated keratinocytes and the inner hair root sheath. 9 In the epidermis, corneodesmosin is stored within lamellar granules (lamellar bodies) and secreted from the apical side of cells (Fig. 2) . Secreted corneodesmosin binds to desmosome desmoglea providing stronger cell-cell adhesions (Figs 1,2). Next, corneodesmosin is continuously degraded into smaller components in the stratum corneum, gradually losing its adhesive capability. Corneodesmosin is found as a component of CD surrounding corneocytes in the lower stratum corneum. We have analyzed the timing of corneodesmosin secretion and TJ barrier formation and found that corneodesmosin secretion starts before TJ barrier establishment (Fig. 2) . 10 In this way, corneodesmosin can bind to not only apical desmosomes but also basolateral ones.
The three known components of the extracellular part of CD are desmoglein 1, desmocollin 1 and corneodesmosin. Many proteases including kallikrein-related peptidases (KLK) are involved in CD proteolysis. 11 KLK are a family of 15 secreted serine proteases belonging to the chymotrypsin-like serine endopeptidase family. A member of this family activates itself or other proteases by limited proteolysis in a weblike proteolytic network. KLK are expressed in epidermal keratinocytes, stored within lamellar granules and secreted from the apical side of cells into the extracellular space in the superficial epidermal layers (Fig. 2) . At least KLK1, 5, 6, 7 and 14 are directly involved in the degradation of CD components. The proteolytic activation of KLK in the epidermis starts from KLK5, which is activated by matriptase (ST14), a type II transmembrane serine protease expressed in the uppermost living layer of the epidermis. Lymphoepithelial Kazal-type-related inhibitor (LEKTI) is a well-studied inhibitor of epidermal KLK that is expressed in the epidermal granular layer, stored within lamellar granules and secreted into the extracellular spaces. LEKTI contains 15 protease inhibitory domains (D1-D15) that bind KLK5, 6, 7, 13 and 14 and strongly inhibit their activities. LEKTI needs to be proteolytically processed by furin to become a physiological inhibitor. This proteolytic process generates multiple LEKTI domains containing one to six domains with different inhibitory specificities against KLK. Other less well-studied protease inhibitors are also involved in the regulation of KLK activities. Among these are LEKTI2, SPINK6, SLPI (also known as secretory leukocyte protease inhibitor or antileukoprotease), elafin (also known as proteinase inhibitor 3 or SKALP), SERPINA12 (vaspin) and SerpinB6.
SEVERE DERMATITIS, MULTIPLE ALLERGIES AND METABOLIC WASTING (SAM) SYNDROME
Severe dermatitis, multiple allergies and metabolic wasting syndrome was first described as a novel genodermatosis caused by homozygous loss-of-function mutations in DSG1. 12 Later, a case of SAM syndrome was reported as caused by a dominantly inherited desmoplakin gene mutation. 13 The patients exhibited congenital erythroderma, erosion, scales, palmoplantar keratoderma, hypotrichosis, increased serum immunoglobulin (Ig)E levels, food allergies, various infections and growth retardation. The patient's epidermis showed acantholysis and an uneven distribution of desmosomes in the upper spinous and granular layers (Fig. 3) . Keratin filaments were retracted from the cell membrane to the perinuclear areas. Desmosomes in the basal and lower spinous layer were normal, reflecting that desmoglein 3 is the main desmosomal transmembrane protein in the lower epidermis, and desmoglein 1 is mainly expressed in differentiated keratinocytes.
Heterozygous carriers of the DSG1 loss-of-function mutations developed palmoplantar keratoderma. This finding indicates that when the expression of desmoglein 1 is decreased by half, the lesions appear only in body sites where strong mechanical stress is placed, similar to type I striated palmoplantar keratoderma caused by DSG1 haploinsufficiency mutations. Another SAM syndrome patient showed milder phenotypes with palmoplantar keratoderma, dermatitis and allergies despite the absence of desmoglein 1 expression. 14 Interestingly, desmocollin 1 expression is increased in this case, probably due to a compensatory mechanism. Another family with mild SAM syndrome has also been reported. 15 Intrafamilial differences in disease severities have also been reported. 16 A case with SAM syndrome caused by a heterozygous missense mutation in the N-terminal domain of desmoplakin showed erythroderma, ichthyosis, palmoplantar keratoderma, nail dystrophy and diffuse alopecia. 13 Severe pruritus, low bodyweight, short height, macrocephaly, global developmental delay, nystagmus, superficial pustulosis, repeated sepsis, keratitis, photophobia, frequent vomiting, abdominal pain, diarrhea and food aversion were also observed. Eosinophilia, increased serum IgE levels and specific IgE against multiple food allergens were detected as well. Electron microscopy showed poor attachment between keratin filaments and desmosomes and poor development of desmosomal inner plaques in the spinous layer. An immunofluorescent study showed an abnormal distribution of desmoplakin, which was not at the cell membrane but aggregated within the cytoplasm. Desmoplakin is an obligatory component of desmosomes and is highly expressed in the myocardium, epidermis and hair follicles. Desmoplakin interacts with intermediate filaments through its C-terminal domain and anchors them into desmosomal plaques and interacts with plakophilin 1 and plakoglobin via the N-terminal domain. Interestingly, the expression of DSG1 was greatly decreased in SAM syndrome patients with the desmoplakin mutation. This result is likely because mutant desmoplakin could not form stable complexes with DSG1.
NETHERTON SYNDROME
Netherton syndrome is a rare autosomal recessive condition affecting approximately one in 200 000 newborn children. 17 Patients exhibit ichthyosis and hair shaft abnormalities, such as trichorrhexis invaginata and atopic features. Ichthyosis can be generalized as ichthyosiform erythroderma or localized as ichthyosis linearis circumflexa. Bacterial and viral infection of the skin is commonly seen. Patients may also display growth retardation, asthma, food allergies and elevated serum IgE levels. Netherton syndrome is caused by mutations in SPINK5 (serine protease inhibitor Kazal-type 5), which encodes LEKTI. Because of LEKTI dysfunction, KLK are overactivated in the patients' skin, which leads to accelerated desquamation and barrier defects. An ultrastructural investigation showed early degradation of (corneo-) desmosomes (Fig. 4) . 18 The pathological mechanisms associated with Netherton syndrome have been studied using several mouse models. In these studies, LEKTIdeficient mice died shortly after birth due to dehydration. 19, 20 Simultaneous ablation of KLK5 greatly improved the skin phenotypes associated with LEKTI-deficiency, but ablation of KLK7 did not improve these phenotypes. However, the simultaneous ablation of both KLK5 and KLK7 completely rescued the epidermal barrier and the postnatal lethality, allowing mice to reach adulthood with fully functional skin and normal hair growth. 20 This indicates that unregulated KLK5 and KLK7 activation are responsible for the development of Netherton syndrome. Simultaneous ablation of matriptase and LEKTI also rescued the symptoms, indicating a critical role for matriptase in the initiation of the KLK activation network. 21 Another mouse overexpressing KLK5 in the epidermal granular layer showed cutaneous and systemic hallmarks of severe inflammation and allergy with pruritus, which are similar to features of Netherton syndrome. 22 Absence of LEKTI can dysregulate multiple pathways. 17, 19, 22 First, barrier defects due to accelerated desquamation could cause microbe and allergen penetration, danger signals and inflammasome activation. Activated KLK also activate protease-activated receptor-2 (PAR-2), a transmembrane receptor that is highly expressed at the keratinocyte cell surface. Activated PAR-2 induces nuclear factor-jB-mediated overexpression of pro-inflammatory and pro-allergic mediators, such as thymic stromal lymphopoietin, tumor necrosis factor-a, interleukin (IL)-8 and intercellular adhesion molecule 1. Overactivated KLK7 also activates pro-IL-1b into active IL-1b.
Moreover, the production of downstream cytokines is known to attract mast cells and eosinophils and activate T-helper (Th) 2/Th17/Th22 cells. Based on these pathophysiological mechanisms, the therapeutic potential of KLK inhibitors has been proposed. 23 A study protocol for a phase I trial for the feasibility and safety evaluations of autologous epidermal sheets generated from ex vivo gene-corrected keratinocyte stem cells, which will be grafted into patients with Netherton syndrome, has also been published. 24 
INFLAMMATORY TYPE PEELING SKIN DISEASE (PEELING SKIN SYNDROME TYPE B)
This disease is a rare recessive skin condition characterized by lifelong patchy peeling of the superficial epidermis, which affects the entire body with onset at birth or shortly thereafter. 25 This condition is associated with pruritus and atopy.
Several patients have been reported with high IgE levels. These clinical features overlap with those of Netherton syndrome, though this disease is not associated with hair abnormalities. This disease is caused by loss-of-function mutations or the complete deletion of CDSN. [25] [26] [27] Heterozygous carriers do not present any clinical symptoms. Peeling of the stratum corneum occurs because the patients' CD lack corneodesmosin molecules in their extracellular spaces. Ultrastructural examination detected abnormal desmoglea and intercellular splitting at the superficial epidermal granular layers (Fig. 4) . 26 Inflammatory responses and cytokine expression were studied in detail in a mice model of this disease, where corneodesmosin is ablated in an inducible manner. 28 Type 2 and 17 inflammatory responses developed simultaneously and blocking IL-1 signaling suppressed both reactions and ameliorated skin inflammation. These results suggest IL-1 as a potential therapeutic target in this disease.
CONCLUSIONS
By correlating ultrastructural changes to molecular and biochemical changes in diseases, we can more deeply understand pathological mechanisms. We hope this review encourages skin researchers to pay greater attention to morphologies in skin diseases. 
